Inspire Medical Systems, Inc. (NYSE:INSP) Given Consensus Rating of “Hold” by Brokerages

Inspire Medical Systems, Inc. (NYSE:INSP) has received an average rating of “Hold” from the twenty analysts that are currently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a sell recommendation, thirteen have issued a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $81.8421.

Several research firms have recently commented on INSP. Bank of America downgraded Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 price objective for the company. in a report on Friday, May 22nd. Truist Financial dropped their price objective on shares of Inspire Medical Systems from $64.00 to $50.00 and set a “hold” rating on the stock in a research note on Tuesday, May 5th. Piper Sandler lowered shares of Inspire Medical Systems from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $85.00 to $55.00 in a research note on Tuesday, May 5th. Weiss Ratings lowered shares of Inspire Medical Systems from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, May 6th. Finally, Summit Redstone set a $39.00 price objective on shares of Inspire Medical Systems in a research note on Friday, May 22nd.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Wellington Management Group LLP bought a new stake in Inspire Medical Systems during the fourth quarter worth $203,929,000. M&T Bank Corp bought a new stake in Inspire Medical Systems during the fourth quarter worth $85,871,000. Deerfield Management Company L.P. grew its holdings in Inspire Medical Systems by 648.4% during the third quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock worth $77,739,000 after buying an additional 907,694 shares in the last quarter. Morgan Stanley grew its holdings in Inspire Medical Systems by 179.5% during the fourth quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock worth $116,188,000 after buying an additional 809,121 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. bought a new stake in Inspire Medical Systems during the fourth quarter worth $61,619,000. 94.91% of the stock is owned by institutional investors.

Inspire Medical Systems Stock Performance

Shares of INSP opened at $40.73 on Friday. Inspire Medical Systems has a 52-week low of $39.27 and a 52-week high of $147.03. The business’s 50 day moving average price is $49.83 and its two-hundred day moving average price is $74.50. The firm has a market cap of $1.17 billion, a PE ratio of 9.07, a price-to-earnings-growth ratio of 4.22 and a beta of 0.73.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings results on Monday, May 4th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.38. The firm had revenue of $204.58 million for the quarter, compared to analyst estimates of $200.04 million. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.The company’s revenue was up 1.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.10 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. Research analysts predict that Inspire Medical Systems will post 0.91 EPS for the current fiscal year.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.